文献类型：期刊文献

英文题名：Pan-Cancer Multi-Omics Analysis Reveals the Potential of ZDHHC16 in Tumor Progression and Immune Regulation

作者：Zhang, Haolong[1,2];Wu, Sen[2];Ma, Yufei[2];Yang, Yufei[1];Zhang, Yixin[2];Liu, Xue Hai[1];Zhang, Haoling[3];Zhang, Zheng[2]

第一作者：Zhang, Haolong;张虎林;张惠玲

通信作者：Zhang, Z[1];Zhang, HL[2]

机构：[1]Gansu Univ Chinese Med, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China;[2]Henan Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China;[3]Univ Sains Malaysia, Adv Med & Dent Inst, Kepala Batas, Penang, Malaysia

第一机构：甘肃中医药大学公共卫生学院

通信机构：[1]corresponding author), Henan Med Univ, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China;[2]corresponding author), Univ Sains Malaysia, Adv Med & Dent Inst, Kepala Batas, Penang, Malaysia.

年份：2026

卷号：108

期号：2

外文期刊名：CHEMICAL BIOLOGY & DRUG DESIGN

收录：;Scopus(收录号：2-s2.0-105046785305);WOS:【SCI-EXPANDED(收录号:WOS:001844164200001)】；

基金：Key R&D Program of International Science and Technology Cooperation of Gansu Provincial Science and Technology Plan (Grant 23YFWA0005). Gansu Provincial University Innovation Fund Project (Grant 2025A-110). Northwest Center for Collaborative Innovation of Traditional Chinese Medicine on Prevention and Control of Nutrition and Environment-Related Diseases (Grant ZYXT-24-02). Natural Science Foundation of Gansu Province (Grant 22JR5RA582, 5.2023A0-088, 2023A-088).

语种：英文

外文关键词：multi-omics; pan-cancer; S-palmitoylation; ZDHHC16

摘要：S-palmitoylation is a crucial post-translational modification that regulates diverse cellular processes, particularly signalling pathways. The ZDHHC family of enzymes catalyzes this modification, however, the role of ZDHHC16 in cancer warrants in-depth investigation. This study presents a comprehensive pan-cancer analysis of ZDHHC16, examining its expression patterns, clinical relevance, associations with immune responses, genomic characteristics, and potential as a therapeutic target. We further analysed single-cell and spatial transcriptomic data to identify specific cell populations associated with ZDHHC16 dysregulation. Our findings reveal that ZDHHC16 dysregulation is tissue-specific and promotes tumor progression and modulates immune responses, highlighting its potential as a therapeutic target in several cancers, including ACC and BRCA. In ACC and BRCA, high ZDHHC16 expression correlates with shorter overall survival (p < 0.001) and regulates PD-L1 expression.